Abstract
Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.
| Original language | English |
|---|---|
| Pages (from-to) | 204-209 |
| Number of pages | 6 |
| Journal | Oncology |
| Volume | 59 |
| Issue number | 3 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Doxifluridine
- Hepatocellular carcinoma
- Oral chemotherapy
- Phase II study
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Oral doxifluridine in advanced hepatocellular carcinoma : A phase II study. / Lencioni, Monica; Falcone, Alfredo; Allegrini, Giacomo; Pfanner, Elisabetta; Masi, Gianluca; Brunetti, Isa; Di Marsico, Roberta; Fontana, Eloise; Orlandini, Cinzia; Stampino, Corrado Gallo; Bartolozzi, Carlo; Conte, Pier Franco.
In: Oncology, Vol. 59, No. 3, 2000, p. 204-209.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Oral doxifluridine in advanced hepatocellular carcinoma
T2 - A phase II study
AU - Lencioni, Monica
AU - Falcone, Alfredo
AU - Allegrini, Giacomo
AU - Pfanner, Elisabetta
AU - Masi, Gianluca
AU - Brunetti, Isa
AU - Di Marsico, Roberta
AU - Fontana, Eloise
AU - Orlandini, Cinzia
AU - Stampino, Corrado Gallo
AU - Bartolozzi, Carlo
AU - Conte, Pier Franco
PY - 2000
Y1 - 2000
N2 - Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.
AB - Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.
KW - Doxifluridine
KW - Hepatocellular carcinoma
KW - Oral chemotherapy
KW - Phase II study
UR - http://www.scopus.com/inward/record.url?scp=0033764698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033764698&partnerID=8YFLogxK
M3 - Article
C2 - 11053987
AN - SCOPUS:0033764698
VL - 59
SP - 204
EP - 209
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 3
ER -